Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2025 and raised its full year 2025 guidance.

The company reported revenue of $2.5 billion for the second quarter of 2025, an increase of 4% compared with the second quarter of 2024. On an organic operational1 basis, revenue for the second quarter of 2025 increased 8% compared with the second quarter of 2024. Net income for the second quarter of 2025 was $718 million, or $1.61 per diluted share, an increase of 15% and 18%, respectively, on a reported basis.

Adjusted net income2 for the second quarter of 2025 was $783 million, or $1.76 per diluted share, an increase of 10% and 13%, respectively, on both a reported and an organic operational basis. Adjusted net income for the second quarter of 2025 excludes the net impact of $65 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.

EXECUTIVE COMMENTARY
“Zoetis delivered a strong broad-based performance in the second quarter of 2025, with 8% organic operational revenue growth," said Kristin Peck, Chief Executive Officer of Zoetis. "Our consistent results across economic and competitive cycles reflect the strength of our innovation engine, the breadth of our diversified portfolio and the discipline of our execution in what remains one of the most compelling long-term growth sectors. As we look to the second half of the year, our focus remains clear: execute with discipline, advance meaningful innovation and stay deeply connected to our customers."

QUARTERLY HIGHLIGHTS
Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the second quarter of 2025:

  • Revenue in the U.S. segment was $1.4 billion, an increase of 4% compared with the second quarter of 2024 and an increase of 7% on an organic operational basis. Sales of the company's innovative companion animal products increased 9%, driven primarily by Simparica Trio®, the company’s flea, tick and heartworm combination product, as well as its key dermatology portfolio including Apoquel®, Apoquel Chewable and Cytopoint®. Broad-based growth across the remainder of the companion animal portfolio, including vaccines and diagnostics, was partially offset by a decline in the company's monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela® for dogs and Solensia® for cats. Sales of livestock products declined 21% in the quarter, largely due to the divestiture of the medicated feed additive (MFA) product portfolio and related assets. On an organic operational basis, sales of livestock products decreased 2% in the quarter due to the timing of supply of ceftiofur products and competition for Draxxin, partially offset by growth across the livestock portfolio, primarily in vaccines.

  • Revenue in the International segment was $1.1 billion, a 3% increase on a reported basis and an increase of 9% on an organic operational basis compared with the second quarter of 2024. Sales of companion animal products grew 8% on a reported and an operational3 basis. Growth in the quarter was driven by the company's innovative companion animal portfolio including key dermatology products Apoquel and Cytopoint, Simparica franchise and monoclonal antibodies for OA pain, Librela and Solensia. Sales of livestock products declined 2% on a reported basis, largely due to the divestiture of the MFA product portfolio and related assets, as well as foreign exchange. On an organic operational basis, sales of livestock products increased 10%, driven by broad-based growth across core species including swine, fish, poultry and cattle.

INVESTMENTS IN GROWTH
Zoetis continues to advance care for animals across the globe with a robust pipeline fueled by lifecycle innovation, geographic expansion and disruptive innovation. The company expects a significant approval in a major market every year for the next several years.

Since its last quarterly earnings announcement, Simparica Trio gained new label indications in Japan to prevent eyeworms and to prevent Dipylidium caninum (flea tapeworm) infections by killing Ctenocephalides felis vector fleas in treated dogs. With this approval, Simparica Trio is the only canine combination parasiticide indicated to prevent flea tapeworm infections, at the source, by killing vector fleas before transmission. Revolution® Plus (selamectin/sarolaner), a topical combination product that treats ticks, fleas, ear mites, lice and gastrointestinal worms and prevents heartworm disease in cats, received approval for an additional claim related to efficacy against notoedres mange in Australia, and in the EU received approval for an additional claim for the prevention of flea tapeworm infections by controlling fleas.

Geographic expansion included approval of Solensia (frunevetmab injection) in South Korea for control of pain associated with osteoarthritis in cats. Revolution Plus was approved in the Philippines to treat ticks, fleas, ear mites, lice and gastrointestinal worms and prevent heartworm disease in cats.

On the livestock side of the business, Zoetis received a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus, for use in lactating dairy cattle in the U.S. In Brazil, the company gained a new label claim for Fostera® Gold PCV MH related to swine breeding herd safety. Zoetis received approval in Australia for needle-free administration of its Fostera Gold PCV MH vaccineto help prevent infection from Mycoplasma hyopneumoniae and Porcine circovirus, andits Fostera Gold PCV Metastim vaccine to help prevent infection from Porcine circovirus. In the EU, the company received approval for a needle-free microdose of Suvaxyn® PRRS, a vaccine that helps prevent porcine respiratory and reproductive syndrome.

FINANCIAL GUIDANCE
Zoetis is raising its full year 2025 guidance due to a strong first-half performance and continued discipline in execution and cost management.

  • Revenue between $9.450 billion to $9.600 billion (organic operational growth of 6.5% to 8.0%)

  • Reported net income between $2.650 billion to $2.700 billion

  • Adjusted net income between $2.825 billion to $2.875 billion (organic operational growth of 5.5% to 7.5%)

  • Reported diluted EPS of $5.90 to $6.00

  • Adjusted diluted EPS between $6.30 to $6.40

This guidance reflects foreign exchange rates as of late July and the impact of enacted and assumptions on announced tariffs. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call this morning.

WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review second quarter 2025 results, discuss financial guidance and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. A replay of the webcast will be archived and made available on August 5, 2025.

About Zoetis
As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.

1 Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.

2 Adjusted net income and its components and adjusted diluted earnings per share (non-GAAP financial measures) are defined as reported net income and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.

3 Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.

DISCLOSURE NOTICES
Forward-Looking Statements: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding financial impact of divestitures; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; foreign exchange rates, tax rates, tariffs, changes in tax regimes and laws and any changes thereto; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share, operational results (which exclude the impact of foreign exchange) and organic operational results (which exclude the impact of foreign exchange and certain acquisitions and divestitures), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.

Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on LinkedIn, Facebook, X (formerly Twitter) and YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.

ZTS-COR
ZTS-IR
ZTS-FIN

ZOETIS INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME(a)

(UNAUDITED)

(millions of dollars, except per share data)

Three Months Ended

Six Months Ended

June 30,

June 30,

2025

2024

% Change

2025

2024

% Change

Revenue

$

2,460

$

2,361

4

$

4,680

$

4,551

3

Costs and expenses:

Cost of sales

649

668

(3

)

1,271

1,311

(3

)

Selling, general and administrative expenses

617

581

6

1,180

1,128

5

Research and development expenses

172

171

1

329

333

(1

)

Amortization of intangible assets

33

35

(6

)

65

72

(10

)

Restructuring charges and certain acquisition and divestiture-related costs

30

42

(29

)

30

46

(35

)

Interest expense, net of capitalized interest

53

59

(10

)

107

117

(9

)

Other (income)/deductions–net

4

25

(84

)

(14

)

17

*

Income before provision for taxes on income

902

780

16

1,712

1,527

12

Provision for taxes on income

184

156

18

363

304

19

Net income before allocation to noncontrolling interests

718

624

15

1,349

1,223

10

Less: Net income/(loss) attributable to noncontrolling interests

—

—

*

—

—

*

Net income attributable to Zoetis Inc.

$

718

$

624

15

$

1,349

$

1,223

10

Earnings per share attributable to Zoetis—basic

$

1.61

$

1.37

18

$

3.02

$

2.68

13

Earnings per share attributable to Zoetis—diluted

$

1.61

$

1.37

18

$

3.02

$

2.67

13

Weighted-average shares used to calculate earnings per share

Basic

445.1

455.5

446.3

456.7

Diluted

445.5

456.0

446.7

457.4

(a)The condensed consolidated statements of income present the three and six months ended June 30, 2025 and 2024. Subsidiaries operating outside the United States are included for the three and six months ended May 31, 2025 and 2024.

* Calculation not meaningful.

ZOETIS INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per share data)

Three Months Ended June 30, 2025

GAAP Reported(a)

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(b)

Cost of sales

$

649

$

(1

)

$

—

$

(1

)

$

647

Gross profit

1,811

1

—

1

1,813

Selling, general and administrative expenses

617

(3

)

—

(9

)

605

Amortization of intangible assets

33

(28

)

—

—

5

Restructuring charges and certain acquisition and divestiture-related costs

30

—

(1

)

(29

)

—

Other (income)/deductions–net

4

—

—

(8

)

(4

)

Income before provision for taxes on income

902

33

1

47

983

Provision for taxes on income

184

7

—

9

200

Net income attributable to Zoetis

718

26

1

38

783

Earnings per common share attributable to Zoetis–diluted

1.61

0.06

—

0.09

1.76

Three Months Ended June 30, 2024

GAAP Reported(a)

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(b)

Cost of sales

$

668

$

(1

)

$

—

$

—

$

667

Gross profit

1,693

1

—

—

1,694

Selling, general and administrative expenses

581

(3

)

—

—

578

Amortization of intangible assets

35

(31

)

—

—

4

Restructuring charges and certain acquisition and divestiture-related costs

42

—

(5

)

(37

)

—

Other (income)/deductions–net

25

—

—

(33

)

(8

)

Income before provision for taxes on income

780

35

5

70

890

Provision for taxes on income

156

8

1

14

179

Net income attributable to Zoetis

624

27

4

56

711

Earnings per common share attributable to Zoetis–diluted

1.37

0.06

0.01

0.12

1.56

(a) The condensed consolidated statements of income present the three months ended June 30, 2025 and 2024. Subsidiaries operating outside the United States are included for the three months ended May 31, 2025 and 2024.

(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.

See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

ZOETIS INC.

RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars, except per share data)

Six Months Ended June 30, 2025

GAAP Reported(a)

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(b)

Cost of sales

$

1,271

$

(2

)

$

—

$

(2

)

$

1,267

Gross profit

3,409

2

—

2

3,413

Selling, general and administrative expenses

1,180

(6

)

—

(15

)

1,159

Research and development expenses

329

(1

)

—

—

328

Amortization of intangible assets

65

(56

)

—

—

9

Restructuring charges and certain acquisition and divestiture-related costs

30

—

(1

)

(29

)

—

Other (income)/deductions–net

(14

)

—

—

(7

)

(21

)

Income before provision for taxes on income

1,712

65

1

53

1,831

Provision for taxes on income

363

14

—

9

386

Net income attributable to Zoetis

1,349

51

1

44

1,445

Earnings per common share attributable to Zoetis–diluted

3.02

0.11

—

0.10

3.23

Six Months Ended June 30, 2024

GAAP Reported(a)

Purchase Accounting Adjustments

Acquisition and Divestiture- Related Costs(1)

Certain Significant Items(2)

Non-GAAP Adjusted(b)

Cost of sales

$

1,311

$

(2

)

$

—

$

—

$

1,309

Gross profit

3,240

2

—

—

3,242

Selling, general and administrative expenses

1,128

(6

)

—

—

1,122

Research and development expenses

333

(1

)

—

—

332

Amortization of intangible assets

72

(63

)

—

—

9

Restructuring charges and certain acquisition and divestiture-related costs

46

—

(5

)

(41

)

—

Other (income)/deductions–net

17

—

—

(35

)

(18

)

Income before provision for taxes on income

1,527

72

5

76

1,680

Provision for taxes on income

304

16

1

14

335

Net income attributable to Zoetis

1,223

56

4

62

1,345

Earnings per common share attributable to Zoetis–diluted

2.67

0.12

0.01

0.14

2.94

(a) The condensed consolidated statements of income present the six months ended June 30, 2025 and 2024. Subsidiaries operating outside the United States are included for the six months ended May 31, 2025 and 2024.

(b) Non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS. Despite the importance of these measures to management in goal setting and performance measurement, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, non-GAAP adjusted net income and its components and non-GAAP adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Non-GAAP adjusted net income and its components, and non-GAAP adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance.

See Notes to Reconciliation of GAAP Reported to Non-GAAP Adjusted Information for notes (1) and (2).

ZOETIS INC.

NOTES TO RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION

CERTAIN LINE ITEMS

(UNAUDITED)

(millions of dollars)

(1) Acquisition and divestiture-related costs include the following:

Three Months Ended

Six Months Ended

June 30,

June 30,

2025

2024

2025

2024

Acquisition-related costs(a)

$

1

$

1

$

1

$

1

Divestiture-related costs(b)

—

4

—

4

Total acquisition and divestiture-related costs—pre-tax

1

5

1

5

Income taxes(c)

—

1

—

1

Total acquisition and divestiture-related costs—net of tax

$

1

$

4

$

1

$

4

(a) Acquisition-related costs represent external, incremental costs that directly relate to transacting and integrating businesses, included in Restructuring charges and certain acquisition and divestiture-related costs.

(b) Divestiture-related costs consisted of costs related to the sale of our medicated feed additive product portfolio, certain water soluble products and related assets, included in Restructuring charges and certain acquisition and divestiture-related costs.

(c) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.

(2) Certain significant items include the following:

Three Months Ended

Six Months Ended

June 30,

June 30,

2025

2024

2025

2024

Other restructuring charges and cost-reduction/productivity initiatives(a)

$

7

$

37

$

7

$

41

Business process transformation program(b)

11

—

18

—

Certain asset impairment charges(c)

27

11

27

11

Net loss on sale of business(d)

3

22

3

22

Other

(1

)

—

(2

)

2

Total certain significant items—pre-tax

47

70

53

76

Income taxes(e)

9

14

9

14

Total certain significant items—net of tax

$

38

$

56

$

44

$

62

(a) For the three and six months ended June 30, 2025, primarily consisted of employee termination costs related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs.

For the three and six months ended June 30, 2024, primarily consisted of employee termination costs related to organizational structure refinements, included in Restructuring charges and certain acquisition and divestiture-related costs. For the six months ended June 30, 2024, charges were partially offset by a reversal of certain employee termination costs as a result of a change in strategy from our 2015 operational efficiency initiative.

(b) Represents costs related to our multi-year business process transformation program, which includes the implementation of a new enterprise resource planning (ERP) system, related digital technology solutions and other related costs, included in Selling, general and administrative expenses and Cost of sales. This comprehensive program is a major global and cross-functional company-wide effort that we believe will transform how we work across our business and contribute to all of our strategic priorities. Due to the nature, scope and magnitude of this investment, these costs are incremental transformational costs that are far in excess of the historical normal level of spending to support operations and are not expected to recur in the foreseeable future.

(c) For the three and six months ended June 30, 2025, represents certain asset impairment charges related to a transition from internal to external innovation and manufacturing of certain products and the closure of a related site, included in Restructuring charges and certain acquisition and divestiture-related costs, as well as charges related to our aquaculture product portfolio included in Other (income)/deductions–net.

For the three and six months ended June 30, 2024, represents certain asset impairment charges related to our aquaculture product portfolio included in Other (income)/deductions–net.

(d) Represents a net loss related to the sale of our medicated feed additive product portfolio, certain water soluble products and related assets sold in 2024, included in Other (income)/deductions–net.

(e) Included in Provision for taxes on income. Income taxes include the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction's applicable tax rate.

ZOETIS INC.

ADJUSTED SELECTED COSTS, EXPENSES AND INCOME(a)

(UNAUDITED)

(millions of dollars)

Three Months Ended

June 30,

% Change

2025

2024

Total

Foreign Exchange

Operational(b)

Divestitures

Organic Operational(c)

Adjusted cost of sales

$

647

$

667

(3

)%

(6

)%

3

%

as a percent of revenue

26.3

%

28.3

%

NA

NA

NA

Adjusted SG&A expenses

605

578

5

%

(1

)%

6

%

Adjusted R&D expenses

171

171

—

%

(1

)%

1

%

Adjusted net income

783

711

10

%

3

%

7

%

(3

)%

10

%

Six Months Ended

June 30,

% Change

2025

2024

Total

Foreign Exchange

Operational(b)

Divestitures

Organic Operational(c)

Adjusted cost of sales

$

1,267

$

1,309

(3

)%

(8

)%

5

%

as a percent of revenue

27.1

%

28.8

%

NA

NA

NA

Adjusted SG&A expenses

1,159

1,122

3

%

(2

)%

5

%

Adjusted R&D expenses

328

332

(1

)%

—

%

(1

)%

Adjusted net income

1,445

1,345

7

%

3

%

4

%

(4

)%

8

%

(a) Adjusted cost of sales, adjusted selling, general, and administrative (SG&A) expenses, adjusted research and development (R&D) expenses, and adjusted net income (non-GAAP financial measures) are defined as the corresponding reported U.S. GAAP income statement line items excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. These adjusted income statement line item measures are not, and should not be viewed as, substitutes for the corresponding U.S. GAAP line items. The corresponding GAAP line items and reconciliations of reported to adjusted information are provided in Condensed Consolidated Statements of Income and Reconciliation of GAAP Reported to Non-GAAP Adjusted Information.

(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.

(c) Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.

ZOETIS INC.

2025 GUIDANCE

Selected Line Items

(millions of dollars, except per share amounts)

Full Year 2025

as of August 5, 2025

Full Year 2025

as of May 6, 2025

(Prior Guidance)

Revenue

$9,450 to $9,600

$9,425 to $9,575

Organic operational growth(a)

6.5% to 8.0%

6% to 8%

Adjusted cost of sales as a percentage of revenue(b)

Approximately 28.0%

Approximately 28.5%

Adjusted SG&A expenses(b)

$2,355 to $2,405

$2,340 to $2,390

Adjusted R&D expenses(b)

$690 to $700

$690 to $700

Adjusted interest expense and other (income)/deductions-net(b)

Approximately $170

Approximately $180

Effective tax rate on adjusted income(b)

Approximately 21%

Approximately 21%

Adjusted diluted EPS(b)

$6.30 to $6.40

$6.20 to $6.30

Adjusted net income(b)

$2,825 to $2,875

$2,775 to $2,825

Organic operational growth(a)(c)

5.5% to 7.5%

5% to 7%

Certain significant items and acquisition and divestiture-related costs(d)

Approximately $75

Approximately $45

The guidance as of August 5, 2025 reflects foreign exchange rates as of late July 2025. The prior guidance as of May 6, 2025 reflects foreign exchange rates as of late April 2025.

Reconciliations of 2025 reported guidance to 2025 adjusted guidance follows:

(millions of dollars, except per share amounts)

Reported

Certain significant items and acquisition and divestiture-related costs(d)

Purchase accounting

Adjusted(b)

Cost of sales as a percentage of revenue

~ 28.2%

~ (0.1%)

~ (0.1%)

~ 28.0%

SG&A expenses

$2,395 to $2,445

~ $(30)

~ $(10)

$2,355 to $2,405

R&D expenses

$692 to $702

~ $(2)

$690 to $700

Interest expense and other (income)/deductions-net

~ $170

~ $170

Effective tax rate

~ 21%

~ 21%

Diluted EPS

$5.90 to $6.00

~ $0.15

~ $0.25

$6.30 to $6.40

Net income attributable to Zoetis

$2,650 to $2,700

~ $75

~ $100

$2,825 to $2,875

(a) Organic operational results (a non-GAAP financial measure) excludes the impact of foreign exchange and certain acquisitions and divestitures.

(b) Adjusted net income and its components and adjusted diluted EPS are defined as reported U.S. GAAP net income and its components and reported diluted EPS excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items. Adjusted cost of sales, adjusted SG&A expenses, adjusted R&D expenses, and adjusted interest expense and other (income)/deductions-net are income statement line items prepared on the same basis, and, therefore, components of the overall adjusted income measure. Despite the importance of these measures to management in goal setting and performance measurement, adjusted net income and its components and adjusted diluted EPS are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, have limits in their usefulness to investors. Because of the non-standardized definitions, adjusted net income and its components and adjusted diluted EPS (unlike U.S. GAAP net income and its components and diluted EPS) may not be comparable to the calculation of similar measures of other companies. Adjusted net income and its components and adjusted diluted EPS are presented solely to permit investors to more fully understand how management assesses performance. Adjusted net income and its components and adjusted diluted EPS are not, and should not be viewed as, substitutes for U.S. GAAP net income and its components and diluted EPS.

(c) We do not provide a reconciliation of forward-looking non-GAAP adjusted net income operational results to the most directly comparable U.S. GAAP reported financial measure because we are unable to calculate with reasonable certainty the foreign exchange impact of unusual gains and losses, acquisition and divestiture-related expenses, potential future asset impairments and other certain significant items, without unreasonable effort. The foreign exchange impacts of these items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP reported results for the guidance period.

(d) Primarily includes certain nonrecurring costs related to acquisitions, divestitures and other charges.

ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)

(millions of dollars)

Three Months Ended

June 30,

% Change

2025

2024

Total

Foreign Exchange

Operational(b)

Divestitures

Organic Operational(c)

Revenue:

Companion Animal

$

1,788

$

1,649

8

%

—

%

8

%

—

%

8

%

Livestock

638

694

(8

)%

(2

)%

(6

)%

(12

)%

6

%

Contract Manufacturing & Human Health

34

18

89

%

(2

)%

91

%

—

%

91

%

Total Revenue

$

2,460

$

2,361

4

%

(1

)%

5

%

(3

)%

8

%

U.S.:

Companion Animal

$

1,176

$

1,080

9

%

—

%

9

%

—

%

9

%

Livestock

180

228

(21

)%

—

%

(21

)%

(19

)%

(2

)%

Total U.S. Revenue

$

1,356

$

1,308

4

%

—

%

4

%

(3

)%

7

%

International:

Companion Animal

$

612

$

569

8

%

—

%

8

%

—

%

8

%

Livestock

458

466

(2

)%

(3

)%

1

%

(9

)%

10

%

Total International Revenue

$

1,070

$

1,035

3

%

(2

)%

5

%

(4

)%

9

%

Companion Animal:

Dogs and Cats

$

1,716

$

1,581

9

%

—

%

9

%

Horses

72

68

6

%

—

%

6

%

Total Companion Animal Revenue

$

1,788

$

1,649

8

%

—

%

8

%

Livestock:

Cattle

$

320

$

350

(9

)%

(3

)%

(6

)%

Swine

119

130

(8

)%

(1

)%

(7

)%

Poultry

103

132

(22

)%

(1

)%

(21

)%

Fish

74

62

19

%

1

%

18

%

Sheep and other

22

20

10

%

1

%

9

%

Total Livestock Revenue

$

638

$

694

(8

)%

(2

)%

(6

)%

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.

(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.

ZOETIS INC.

CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES

(UNAUDITED)

(millions of dollars)

Six Months Ended

June 30,

% Change

2025

2024

Total

Foreign Exchange

Operational(b)

Divestitures

Organic Operational(c)

Revenue:

Companion Animal

$

3,334

$

3,099

8

%

(1

)%

9

%

—

%

9

%

Livestock

1,283

1,414

(9

)%

(3

)%

(6

)%

(13

)%

7

%

Contract Manufacturing & Human Health

63

38

66

%

(4

)%

70

%

—

%

70

%

Total Revenue

$

4,680

$

4,551

3

%

(2

)%

5

%

(4

)%

9

%

U.S.:

Companion Animal

$

2,149

$

1,978

9

%

—

%

9

%

—

%

9

%

Livestock

390

493

(21

)%

—

%

(21

)%

(19

)%

(2

)%

Total U.S. Revenue

$

2,539

$

2,471

3

%

—

%

3

%

(4

)%

7

%

International:

Companion Animal

$

1,185

$

1,121

6

%

(3

)%

9

%

—

%

9

%

Livestock

893

921

(3

)%

(5

)%

2

%

(9

)%

11

%

Total International Revenue

$

2,078

$

2,042

2

%

(4

)%

6

%

(4

)%

10

%

Companion Animal:

Dogs and Cats

$

3,197

$

2,965

8

%

(1

)%

9

%

Horses

137

134

2

%

(2

)%

4

%

Total Companion Animal Revenue

$

3,334

$

3,099

8

%

(1

)%

9

%

Livestock:

Cattle

$

678

$

741

(9

)%

(5

)%

(4

)%

Swine

230

257

(11

)%

(4

)%

(7

)%

Poultry

209

271

(23

)%

(3

)%

(20

)%

Fish

127

107

19

%

(1

)%

20

%

Sheep and other

39

38

3

%

(1

)%

4

%

Total Livestock Revenue

$

1,283

$

1,414

(9

)%

(3

)%

(6

)%

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.

(c) Organic operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange and certain acquisitions and divestitures.

ZOETIS INC.

CONSOLIDATED REVENUE BY KEY INTERNATIONAL MARKETS

(UNAUDITED)

(millions of dollars)

Three Months Ended

June 30,

% Change

2025

2024

Total

Foreign Exchange

Operational(a)

Total International

$

1,070

$

1,035

3

%

(2

)%

5

%

Australia

83

83

—

%

(4

)%

4

%

Brazil

93

99

(6

)%

(11

)%

5

%

Canada

73

75

(3

)%

(3

)%

—

%

Chile

36

31

16

%

(3

)%

19

%

China

72

68

6

%

—

%

6

%

France

33

34

(3

)%

3

%

(6

)%

Germany

58

58

—

%

1

%

(1

)%

Italy

38

36

6

%

4

%

2

%

Japan

45

39

15

%

5

%

10

%

Mexico

38

46

(17

)%

(17

)%

—

%

Spain

37

33

12

%

4

%

8

%

United Kingdom

77

73

5

%

4

%

1

%

Other developed markets

162

138

17

%

2

%

15

%

Other emerging markets

225

222

1

%

(1

)%

2

%

Six Months Ended

June 30,

% Change

2025

2024

Total

Foreign Exchange

Operational(a)

Total International

$

2,078

$

2,042

2

%

(4

)%

6

%

Australia

158

156

1

%

(5

)%

6

%

Brazil

181

200

(10

)%

(16

)%

6

%

Canada

140

136

3

%

(5

)%

8

%

Chile

70

62

13

%

(2

)%

15

%

China

132

144

(8

)%

—

%

(8

)%

France

73

75

(3

)%

(2

)%

(1

)%

Germany

109

109

—

%

(1

)%

1

%

Italy

67

64

5

%

—

%

5

%

Japan

81

76

7

%

1

%

6

%

Mexico

75

90

(17

)%

(16

)%

(1

)%

Spain

70

65

8

%

1

%

7

%

United Kingdom

154

150

3

%

2

%

1

%

Other developed markets

295

265

11

%

(2

)%

13

%

Other emerging markets

473

450

5

%

(5

)%

10

%

(a) Operational revenue results (a non-GAAP financial measure) is defined as revenue results excluding the impact of foreign exchange.

Note: operational revenue results are not reflective of organic operational results.

ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)

(millions of dollars)

Three Months Ended

June 30,

% Change

2025

2024

Total

Foreign Exchange

Operational(b)

U.S.:

Revenue

$

1,356

$

1,308

4

%

—

%

4

%

Cost of Sales

208

232

(10

)%

—

%

(10

)%

Gross Profit

1,148

1,076

7

%

—

%

7

%

Gross Margin

84.7

%

82.3

%

Operating Expenses

218

204

7

%

—

%

7

%

Other (income)/deductions-net

—

—

*

*

*

U.S. Earnings

$

930

$

872

7

%

—

%

7

%

International:

Revenue

$

1,070

$

1,035

3

%

(2

)%

5

%

Cost of Sales

314

342

(8

)%

(9

)%

1

%

Gross Profit

756

693

9

%

2

%

7

%

Gross Margin

70.7

%

67.0

%

Operating Expenses

173

175

(1

)%

(3

)%

2

%

Other (income)/deductions-net

—

—

*

*

*

International Earnings

$

583

$

518

13

%

5

%

8

%

Total Reportable Segments

$

1,513

$

1,390

9

%

2

%

7

%

Other business activities(c)

(134

)

(142

)

(6

)%

Reconciling Items:

Corporate(d)

(321

)

(299

)

7

%

Purchase accounting adjustments(e)

(33

)

(35

)

(6

)%

Acquisition and divestiture-related costs(f)

(1

)

(5

)

(80

)%

Certain significant items(g)

(47

)

(70

)

(33

)%

Other unallocated(h)

(75

)

(59

)

27

%

Total Earnings(i)

$

902

$

780

16

%

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.

(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.

(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.

(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.

(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.

(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses.

(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.

(i) Defined as income before provision for taxes on income.

* Calculation not meaningful.

ZOETIS INC.

SEGMENT(a) EARNINGS

(UNAUDITED)

(millions of dollars)

Six Months Ended

June 30,

% Change

2025

2024

Total

Foreign Exchange

Operational(b)

U.S.:

Revenue

$

2,539

$

2,471

3

%

—

%

3

%

Cost of Sales

407

449

(9

)%

—

%

(9

)%

Gross Profit

2,132

2,022

5

%

—

%

5

%

Gross Margin

84.0

%

81.8

%

Operating Expenses

423

394

7

%

—

%

7

%

Other (income)/deductions-net

—

—

*

*

*

U.S. Earnings

$

1,709

$

1,628

5

%

—

%

5

%

International:

Revenue

$

2,078

$

2,042

2

%

(4

)%

6

%

Cost of Sales

616

655

(6

)%

(11

)%

5

%

Gross Profit

1,462

1,387

5

%

(1

)%

6

%

Gross Margin

70.4

%

67.9

%

Operating Expenses

327

334

(2

)%

(5

)%

3

%

Other (income)/deductions-net

1

—

*

*

*

International Earnings

$

1,134

$

1,053

8

%

1

%

7

%

Total Reportable Segments

$

2,843

$

2,681

6

%

—

%

6

%

Other business activities(c)

(263

)

(274

)

(4

)%

Reconciling Items:

Corporate(d)

(592

)

(587

)

1

%

Purchase accounting adjustments(e)

(65

)

(72

)

(10

)%

Acquisition and divestiture-related costs(f)

(1

)

(5

)

(80

)%

Certain significant items(g)

(53

)

(76

)

(30

)%

Other unallocated(h)

(157

)

(140

)

12

%

Total Earnings(i)

$

1,712

$

1,527

12

%

(a) For a description of each segment, see Zoetis' most recent Annual Report on Form 10-K.

(b) Operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange.

(c) Other business activities includes the research and development costs managed by our research and development organization, as well as our contract manufacturing business and human health business.

(d) Corporate includes, among other things, certain costs associated with information technology, administration expenses, interest income and expense, certain compensation costs and other costs not charged to our operating segments.

(e) Purchase accounting adjustments include certain charges related to the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment not charged to our operating segments.

(f) Acquisition and divestiture-related costs include costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs, as well as costs associated with divesting and disintegrating a portion of our business.

(g) Certain significant items includes substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items primarily include certain asset impairment charges, restructuring charges and implementation costs associated with cost-reduction/productivity initiatives that are not associated with an acquisition, costs related to our business process transformation program, as well as the impact of divestiture gains and losses.

(h) Includes overhead expenses associated with our global manufacturing and supply operations not directly attributable to an operating segment, as well as certain procurement costs.

(i) Defined as income before provision for taxes on income.

* Calculation not meaningful.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250804804269/en/

Ämnen i artikeln
Avatar for Businesswire

Businesswire

Zoetis A

Senast

146,12

1 dag %

0,00%
KöpSälj

1 dag

1 mån

1 år

Just nu: Lundin Minings omsättning slår förväntningarna

Just nu: Clas Ohlsons försäljning växte: "Gynnades av det varma vädret"

Novo Nordisk

Idag, 07:32

Storbanken sänker Novo Nordisk igen – tre dagar efter kapningen

Goldman Sachs sänker återigen riktkursen för den danska läkemedelsbjässen. Här är dagens rekar.

Fonder

Kristofer Barrett om USA-börserna, och raset i Novo Nordisk. Foto: Åsa Swee/Novo/Billie Grace Ward

Igår, 10:58

Förvaltarprofilen om USA: "Finns bubbeltendenser"

"Det finns bubbeltendenser", säger fondförvaltaren om den amerikanska marknaden.

Karnov, Thule, Hacksaw och Röko (vars VD Fredrik Karlsson syns på bild) finns bland fondernas mest och minst populära.

Igår, 11:35

Fondernas största darlings – och aktierna som ratas

Fonder äger över 80% av Karnov-aktien, vilket gör bolaget till det med högst fondägande på Stockholmsbörsen. I andra änden finns börsnykomlingarna Hacksaw och Röko med minst fondägande, visar Placeras genomgång.

Kavaljer-förvaltaren Peter Lindvall tror just nu på Revolution Race och Carasent

4 augusti, 14:26

Förvaltaren tror på aktierna som rasat: "Extra intressant"

Kavaljer-förvaltaren Peter Lindvall tror just nu på Revolution Race, Catella, Carasent - och två aktier som pressats rejält. "Justerar man för kassan värderas Catellas förvaltningsverksamhet till omkring fem gånger vinsten", säger Lindvall.

Konjunktur

Spector pengar

Igår, 11:30

Chefsekonom: Blir ingen sänkning från Riksbanken i närtid

Svensk ekonomi har brottats med hög inflation och svag tillväxt under en sommar som präglats av tullhot och geopolitisk oro. Placera har pratat med två nationalekonomer som ser få ljuspunkter inför hösten.

Malmö genre konjunktur

Igår, 09:33

KI: Budgetutrymme på 34 miljarder – kan ätas upp av försvarssatsningar

Konjunkturinstitutet ser en svensk ekonomi som långsamt försöker resa sig ur en utdragen nedgång – men prognosen är att lågkonjunkturen består även 2026. De offentliga finanserna bedöms vara starka, med utrymme för ofinansierade åtgärder på 34 mdr kr i nästa års budget. Eventuella extra försvarssatsningar kan dock förändra kalkylen.

Mest läst

1

Analytiker ser köpläge i Volvo – spår jätteutdelning på 39 miljarder

2

Lista: Analytikernas favoritaktier – här ser de störst uppsida

3

Efter raset: Här är Novo Nordisks kvartalsrapport

4

Uppgifter: Spanien stoppar planerade köp av amerikanska F 35-plan - El País

5

Lista: Analytikernas favoriter bland investmentbolagen – VEF i topp

Dometic

Igår, 16:12

Alcur ser "betydande" uppsida i rusande Dometic

Dometic har rusat på börsen de senaste månaderna - men det finns fortfarande uppsida i aktien, enligt Alcur Fonder.

Warren buffett

Igår, 13:53

Tungt för Berkshire Hathaway – har tappat "Buffett-premien"

Efter 60 år avgår legendariske Warren Buffett som VD för Berkshire Hathaway. Något som fått bolagets aktiekurs att rasa 14% samtidigt som bolaget ökar sin vinst mot föregående år. Det skriver Financial Times.

Pierce Group

Igår, 14:05

Fjärde AP-fonden minskar i Pierce

Fjärde AP-fonden fortsätter minska sitt innehav i e-handelsbolaget Pierce Group och äger nu motsvarande 4,9 procent av kapitalet och 5,0 procent av rösterna.

Novo Nordisk

Novo Nordisk

Igår, 08:00

Efter raset: Här är Novo Nordisks kvartalsrapport

"Vi vidtar åtgärder för att skärpa vår kommersiella effektivitet", skriver avgående VD:n.

Novo

Igår, 13:07

Analytiker splittrade om Novo Nordisks försäljning av Wegovy

Analyser av Novo Nordisks kvartalsrapport har trillat in. UBS lyfter fram att läkemedlet Wegovys försäljning var bättre än väntat – medan JP Morgan beskriver den som "mindre positiv".

Novo Nordisk föll tungt på börsen, efter en vinstvarning på tisdagen

30 juli, 08:25

De största förlorarna i Novo Nordisks börsras

Novo Nordisk rasar över 20% efter en vinstvarning inför nästa veckas rapport. I ägarlistan finns många svenska fonder som förlorar miljardbelopp i kraschen.

Novo

30 juli, 13:48

3000 Avanza-kunder köpte Novo Nordisk i raset

Trots tisdagens kursfall strömmade Avanzas användare till Novo Nordisk, som blev den mest handlade aktien hos nätmäklaren och fick över 3 000 nya ägare – på en dag.

Lockheed Martins flygplan F-35

Igår, 14:45

Uppgifter: Spanien stoppar planerade köp av F-35-plan

Spanien har avbrutit planerna på att köpa F-35-jaktplan från amerikanska Lockheed Martin.

Investtechs analytiker David Östblad skriver om Hemnet.

Igår, 08:42

Teknisk analys: Sälj Hemnet – köp detta i stället

Investtechs analytiker David Östblad lyfter fram två köpvärda case men sätter sälj på bostadsplattformen Hemnet. Här är dagens tekniska analys.

Epiroc Boomer

Igår, 12:50

Epiroc krymper ledningen

Gruv- och bergbrytningsteknikbolaget Epiroc gör om koncernledningen och inför två nya affärsområden från den 1 september 2025: Equipment & Service samt Tools & Attachments.

Tysklands flagga

Igår, 09:18

Tyskland lägger 1120 miljarder i ny fond

Tyskland förbereder lanseringen av en investeringsfond på 100 miljarder euro för att bidra till att säkra strategiskt viktiga sektorer såsom försvar, energi och kritiska råvaror. Det motsvarar omkring 1120 miljarder svenska kronor.

Aktieråd

Störst uppsida

5 augusti, 14:33

Lista: Analytikernas favoritaktier – här ser de störst uppsida

Nu kan Placera lista de svenska aktierna med störst uppsida till analytikernas genomsnittliga riktkurs.

Investors VD Christian Cederholm, Kinneviks VD Georgi Ganev och Industrivärdens VD Helena Stjernholm.

5 augusti, 16:04

Analytikernas favoriter bland investmentbolagen

Hur ser analytikerna på investmentbolagen? Placera har svaret.

Volvo

5 augusti, 13:04

Analytiker ser köpläge i Volvo – spår jätteutdelning på 39 miljarder

Volvos försäljning kommer lyfta tvåsiffrigt nästa år. Vinsten likaså. Det spår Handelsbankens analytiker Hampus Engellau som har en köprekommendation på aktien.

Mt2 9493

5 augusti, 16:29

Miljardären ökar i egna bolaget: "Selektiv"

Grundaren Per Taube har gjort mindre insynsköp i Arlandastad. "När det gäller fastighetsbolag måste man vara selektiv och långsiktig", säger han till Affärsvärlden.

Försvarsminister Pål Jonson (M)

5 augusti, 14:10

Svenskt miljardstöd till Ukrainas försvar

Sverige bidrar med 275 miljoner dollar, motsvarande runt 2,7 miljarder kronor, till ett amerikanskt initiativ för Ukraina.

Analys

Placeras analytiker Daniel Svensson och Anton Ingves skriver om Physitrack

5 augusti, 08:45

Physitrack: Ett hälsosamt val till portföljen

Physitracks plattform för digital sjukgymnastik används årligen av över 7 miljoner människor. Senaste åren har den dock överskuggats av felsatsningar, dyra förvärv och en ansträngd balansräkning. Nu verkar bolaget ha rehabiliterat tidigare snedsteg.

Daniel Svensson skriver om Trelleborg

4 augusti, 11:57

Slå till på Trelleborg – ett rimligt val i verkstaden

De senaste årens förvärv har format ett förnyat Trelleborg där medicinteknik blivit en större del av affären. Den dämpade industrikonjunkturen gör det dock svårt att se koncernens fulla potential, men vi anar att den är god nog för att aktien kan bli bra.

Kopia av kempower juli 2025

1 augusti, 12:28

Laddat för tillväxt i Kempower

Finska Kempower är en av Europas ledande aktörer inom snabbladdare för elfordon. Den historiska tillväxten är imponerande och nu verkar bolaget åter få fart efter ett svagt 2024. Det har dock börsen redan hunnit upptäcka.

Erik holmberg

5 augusti, 13:33

"Gula linjen kan vara intressant ur ett investeringsperspektiv"

Yteffektiva lägenheter och hus med bergvärme är populärt på bostadsmarknaden. Och nu borde den som ska köpa bostad titta på områden "där tunnelbanan byggs ut", enligt Hemnets analytiker Erik Holmberg.

Xi Jinping Donald Trump Kina USA

5 augusti, 15:01

Trump: Nära en förlängning av tullvapenvila med Kina

USA:s president Donald Trump uppger i en intervju med CNBC att han är "mycket nära" ett avtal med Kina för att förlänga den tullvapenvila som löper ut den 12 augusti.

Oljebolaget IPC

5 augusti, 07:58

Familjen Lundins oljebolag IPC minskar vinsten

Oljebolaget IPC redovisar ett ebitda-resultat om 51,5 miljoner dollar för det andra kvartalet 2025 (104).

Senaste nytt

Clas Ohlson

Idag, 07:56

Clas Ohlsons försäljning växte: "Gynnades av det varma vädret"

Lundin Mining

Idag, 07:49

Lundin Minings omsättning slår förväntningarna

Aktierekommendationer

Idag, 07:32

Storbanken sänker Novo Nordisk igen – tre dagar efter kapningen

White Pearl Technology Group

Igår, 17:56

Volvo och ABB åt olika håll på Stockholmsbörsen

Dometic Group

Igår, 16:12

Alcur ser "betydande" uppsida i rusande Dometic

Marknadsöversikt

OMX Stockholm 30

1 DAG %

0,15%

Senast

2 566,53

1 mån
Loading market data...
Senaste aktieanalyserna på Placera
Kollage Analys Ny
Privatekonomi med Placeras expert
Karolina Placera

Karolina Palutko Macéus skriver om allt som har med privatekonomi att göra och hur du kan få mer pengar i plånboken.

Affärsvärlden
AFV

Är du kund hos Avanza? Just nu kan du få en unik rabatt på Affärsvärlden. Afv har 28 år i rad utsetts till Sveriges bästa affärsmagasin i en undersökning med börs-VD:ar, finanschefer, IR-chefer och aktieproffs.

Annons
Introduce

för börsens små- och medelstora företag.

Annons
Investtech

Här hittar du våra artiklar om teknisk analys i samarbete med Investtech.

Volvos VD Martin Lundstedt möter analytiker i Tändstickspalatset efter dagens rapportsläppt

Igår, 17:56

Volvo och ABB åt olika håll på Stockholmsbörsen

Stockholmsbörsen avslutade onsdagens handel små indexrörelser.

Zalando

Igår, 13:45

Zalandos vinst växer

Klädjätten Zalando redovisar en omsättning i linje med förväntat under andra kvartalet.

Novo Nordisk

Igår, 11:46

Jefferies: Novo Nordisks forskningsportfölj bantas ned

Jefferies uppger att det danska läkemedelsbolaget Novo Nordisk har stoppat ett flertal projekt i forskningsportföljen, vilket innebär en större minskning av portföljen än i samband med tidigare rapporter.

Tele2

Igår, 09:06

Tele2 bildar tornbolag med GCI

Teleoperatören Tele2 går samman med GCI för att bilda ett pan-baltiskt tornbolag som täcker alla baltiska länder, enligt ett pressmeddelande.

Vitvarujätten Electrolux och investmentbolaget Flerie finns bland dagens rekar

Igår, 07:25

Electrolux sänks – ett investmentbolag höjs

Barclays sänker vitvarujätten Electrolux riktkurs och upprepar råder undervikt. Här är dagens aktierekar.